Envista (NYSE:NVST) Given New $17.50 Price Target at The Goldman Sachs Group

Envista (NYSE:NVST) had its price objective decreased by The Goldman Sachs Group from $20.00 to $17.50 in a research note issued to investors on Friday morning, Benzinga reports. The Goldman Sachs Group currently has a sell rating on the stock.

NVST has been the topic of a number of other reports. William Blair cut shares of Envista from an outperform rating to a market perform rating in a report on Thursday, February 8th. UBS Group initiated coverage on shares of Envista in a research note on Friday, January 5th. They issued a neutral rating and a $26.00 target price for the company. JPMorgan Chase & Co. reduced their price target on Envista from $29.00 to $23.00 and set an overweight rating on the stock in a research report on Thursday. Needham & Company LLC reissued a hold rating on shares of Envista in a research report on Thursday. Finally, TheStreet lowered Envista from a c rating to a d+ rating in a research report on Wednesday, February 7th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. According to MarketBeat.com, Envista presently has an average rating of Hold and a consensus target price of $25.86.

Envista Stock Down 4.1 %

Shares of NYSE NVST traded down $0.81 during midday trading on Friday, reaching $19.00. 2,239,656 shares of the company’s stock traded hands, compared to its average volume of 1,979,218. The company has a market cap of $3.27 billion, a price-to-earnings ratio of -26.40, a P/E/G ratio of 3.83 and a beta of 1.35. The stock’s 50 day simple moving average is $20.66 and its 200-day simple moving average is $22.53. The company has a quick ratio of 1.90, a current ratio of 2.27 and a debt-to-equity ratio of 0.34. Envista has a one year low of $18.09 and a one year high of $36.74.

Envista (NYSE:NVST) last announced its quarterly earnings results on Wednesday, May 1st. The company reported $0.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.05). The company had revenue of $623.60 million during the quarter, compared to analysts’ expectations of $634.85 million. Envista had a negative net margin of 4.70% and a positive return on equity of 5.84%. The company’s revenue was down .6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.38 earnings per share. On average, analysts predict that Envista will post 1.38 EPS for the current fiscal year.

Hedge Funds Weigh In On Envista

Institutional investors have recently bought and sold shares of the business. Nuance Investments LLC increased its stake in shares of Envista by 953.8% in the fourth quarter. Nuance Investments LLC now owns 3,931,054 shares of the company’s stock worth $94,581,000 after acquiring an additional 3,558,031 shares during the period. River Road Asset Management LLC acquired a new stake in Envista during the 4th quarter worth about $54,931,000. Franklin Resources Inc. raised its stake in shares of Envista by 65.3% during the 4th quarter. Franklin Resources Inc. now owns 5,262,092 shares of the company’s stock valued at $126,606,000 after buying an additional 2,077,786 shares during the last quarter. Norges Bank acquired a new position in shares of Envista in the 4th quarter valued at about $42,874,000. Finally, Vanguard Group Inc. boosted its stake in shares of Envista by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 17,167,767 shares of the company’s stock worth $413,056,000 after buying an additional 944,596 shares during the last quarter.

About Envista

Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.